Secondary Logo

Journal Logo

CLINICAL SCIENCE: CONCISE COMMUNICATION

Factors associated with iohexol-based glomerular filtration rate slope over 36 months in HIV-negative and HIV-positive individuals

Lucas, Gregory M.; Atta, Mohamed G.; Zook, Katie; McFall, Allison M.; Mehta, Shruti H.; Fine, Derek M.; Stein, James H.; Schwartz, George J.

Author Information
doi: 10.1097/QAD.0000000000000949

Abstract

Introduction

The risks for acute kidney injury and chronic kidney disease (CKD) are increased in persons with HIV infection [1]. Intrinsic glomerular filtration rate (GFR) markers, most commonly serum creatinine, are widely used in clinical practice to monitor kidney function. However, creatinine is influenced by non-GFR factors and the accuracy of estimating equations can be poor [2]. Some studies suggest that estimating equations do not perform as well in HIV-positive compared with HIV-negative populations [3,4].

GFR measured with an exogenous filtration marker is considered the gold standard, but is time-consuming and rarely done in clinical practice. To date, several groups have presented cross-sectional analyses of exogenously measured GFR in HIV-positive participants [3–6]; however, few data are available regarding longitudinal GFR measures using a gold-standard method. Using GFR measurements based on iohexol plasma disappearance (iGFR), our objectives were to compare longitudinal iGFR trajectories in HIV-positive and HIV-negative participants, and assess the associations of baseline factors with baseline iGFR and iGFR slope in HIV-positive participants.

Methods

Study design

The Mr. Bean study is a cohort in Baltimore, Maryland to assess demographic, behavioral, and viral factors in the progression of kidney and cardiovascular disease [3]. Using flyers and local media, we recruited HIV-positive and HIV-negative participants in a 2 : 1 ratio, with the goal of achieving broadly similar demographic and behavioral characteristics in the two groups. Inclusion criteria included age 18 years or older and estimated GFR at least 60 ml/min per 1.73 m2. Exclusion criteria included history of radiocontrast allergy, pregnancy, diabetes mellitus, uncontrolled hypertension, or life threatening comorbidity.

Measurements and definitions

Participants completed a baseline study visit and up to three annual follow-up visits. At each visit, we collected demographic, behavioral, clinical, pharmaceutical, anthropomorphic, and laboratory data. Estimated GFR was calculated with the creatinine-based CKD-EPI equation [7]. Active cocaine use was defined by self-report or toxicologic detection of cocaine. Hepatitis C virus (HCV) infection was defined by antibody reactivity or detectable HCV RNA. We used flow cytometry on fresh whole blood to measure the percentage of CD8+ lymphocytes expressing an activated phenotype, defined by the coexpression of CD38+ and HLA-DR+ surface markers.

We measured iGFR at each visit according to a two-compartment model based on the disappearance of iohexol from serum, as described previously [3,8]. In addition, we measured pulse wave velocity, an index of vascular stiffness, by applanation tonometry and waveform capture at the carotid and femoral arterial sites using the SphygmoCor CPV System (West Ryde, Australia). At the baseline visit, trained technicians measured carotid intima-media thickness using Toshiba Aplio Ultrasound System. The presence of plaque, defined as a focal area of intima–media thickening at least 1.5 mm or 50% thicker than the neighboring wall, was assessed in the common and internal carotid arteries bilaterally [9].

Statistical analysis

We used Fisher's exact test and the Wilcoxon rank-sum test to compare categorical and continuous variables, respectively. We used separate linear regression models to calculate annualized iGFR slopes for each participant with at least two iGFR measures, and compared the distributions of the slopes in HIV-negative and HIV-positive participants. Next, to assess the association of factors with baseline iGFR and subsequent iGFR slope, we used multilevel mixed-effects linear regression models, with random intercepts for each individual and an exchangeable correlation structure for residuals, to account for repeated measures within individuals. Interaction terms between the variable of interest and time (in years) were included in regression models, such that separate coefficients represented the association between the factor and baseline iGFR and the association between the factor and the difference in iGFR slope, respectively. We used REDCap [10] for data management and Stata, version 13 (StataCorp, College Station, Texas, USA) for statistical analyses.

Ethical oversight

Participants provided written informed consent and the Johns Hopkins Medicine Institutional Review Board approved the study.

Results

A total of 291 participants (100 HIV-negative and 191 HIV-positive) had at least one valid iGFR and were included in the analysis. Of these, 26 (8.9%) had one, 30 (10.3%) had two, 66 (22.7%) had three, and 169 (58.1%) had four iGFR measures at annual visits, for a total of 960 iGFR measurements. The median (range) follow-up time was 36.4 months (0, 47.4).

Baseline characteristics have been presented previously [3]. The study sample was over 90% black and had a median age of 49 years (Table S1, supplemental digital content https://links.lww.com/QAD/A821). Compared with HIV-negative participants, HIV-positive participants were significantly more likely to be women (19 vs. 35%, P = 0.006), have a urine albumin-creatinine ratio at least 30 mg/g (6 vs. 20%, P = 0.001), and to have HCV (30 vs. 54%, P < 0.001). Estimated GFR values were similar in HIV-negative and HIV-positive participants (median 103 ml/min per 1.73 m2 in each group, P = 0.79). Ninety-one percent of HIV-positive participants were taking antiretroviral therapy, the median CD4+ cell count was 466 cells/μl, and 80% had HIV RNA below 400 copies/ml. There were no systematic differences in key baseline characteristics according to number of visits completed (Table S2, supplemental digital content https://links.lww.com/QAD/A821).

Among 265 participants (91 HIV-negative and 174 HIV-positive) that had 2 or more iGFR measurements, the distributions of individually calculated slopes were similar in HIV-negative and HIV-positive participants (Fig. 1a). Nine (10%) and 17 (10%) of HIV-negative and HIV-positive participants, respectively, experienced a more than 10 ml/min per 1.73 m2 per year decline in iGFR (P = 1.00). In a mixed-effects model, baseline iGFR was significantly lower in HIV-positive than HIV-negative patients (103.2 vs. 110.8, ml/min per 1.73 m2, P = 0.004); however, iGFR decline was not significantly different in the two groups [iGFR slope, −1.94 vs. −3.28 ml/min per 1.73 m2 per year in HIV-positive and HIV-negative participants, respectively; difference in slopes, 1.34 ml/min per 1.73 m2 per year, 95% confidence interval (CI), −0.22, 2.91, P = 0.092] (Fig. 1b).

Fig. 1
Fig. 1:
Iohexol-based glomerular filtration rate (iGFR) slopes.(a) Boxplot showing distributions of individual iGFR slopes, calculated by ordinary least squares, in HIV-negative (n = 91) and HIV-positive (N = 174) participants who had two or more annual GFR measurements (P = 0.073, Wilcoxon rank-sum test). The white line in the box represents the median, and the lower and upper edges of the box correspond to the 25th and 75th percentiles, respectively. The ‘whiskers’ extend to the highest and lowest data points that are within 1.5 times the interquartile range from the upper and lower edges of the box, respectively. Circles represent individual values that lie beyond the range of the whiskers. (b) Spaghetti plot with linear predicted iGFR slopes. The background lines correspond to individual trajectories of iGFR measurements in 25 randomly selected participants. The dashed line with light shading and the solid line with dark shading correspond to estimated iGFR slopes and 95% confidence intervals for HIV-negative and HIV-positive participants, respectively, calculated with mixed effects linear models (see text).

Among HIV-positive participants, factors that were statistically significantly associated with lower baseline iGFR included female sex, increased age, presence of carotid plaque, and HCV coinfection (Table 1). Tenofovir use and current smoking were significantly associated with higher iGFR at baseline.

Table 1
Table 1:
Unadjusted associations of factors with iohexol-based GFR at baseline and longitudinal GFR slope in 191 HIV-positive participants.

Only three factors were significantly associated with iGFR slope in HIV-positive participants. Higher glycosylated hemoglobin values were associated with slower iGFR decline, whereas an albumin-creatinine ratio at least 30 mg/g was associated with a more rapid iGFR decline compared with those with lower levels of albuminuria (Table 1). Compared with patients with HIV RNA less than 400 copies/ml, those with nonsuppressed viral load had more rapid decline in iGFR (−1.31 vs. −4.69 ml/min per 1.73 m2 per year, P = 0.005). Higher pulse wave velocity values were borderline significantly associated with more rapid GFR decline. In a multivariable model containing variables that were significantly associated with iGFR slope in univariable models, nonsuppressed viral load (−3.09 ml/min per 1.73 m2 per year vs. suppressed viral load, 95% CI −5.48, −0.69) and glycosylated hemoglobin (1.24 ml/min per 1.73 m2 per year per 1 SD increase, 95% CI 0.26, 2.23) remained significantly associated with iGFR slope difference, whereas the association with albuminuria was nonsignificant (−1.98 ml/min per 1.73 m2 per year vs. no albuminuria, 95% CI −4.24, 0.28).

Discussion

In this longitudinal study of iGFR measurements in nondiabetic participants with clinically normal estimated kidney function at baseline, we found that baseline iGFR was significantly lower in HIV-positive than HIV-negative participants, despite nearly identical estimated GFR values in the two groups. However, HIV status was not significantly associated with subsequent iGFR slope.

In HIV-positive patients we found adverse associations between viral factors (HCV coinfection and HIV RNA suppression), albuminuria, and cardiovascular disease indicators (carotid plaque and pulse wave velocity) and iGFR. We found no association between tenofovir or boosted protease inhibitor use and iGFR, with the exception of a significantly higher baseline iGFR in participants taking tenofovir compared with not taking tenofovir, an association that likely reflects selection bias.

We found that HIV-positive participants had a lower baseline iGFR than a demographically similar HIV-negative comparison group, and that nonsuppression of HIV RNA was associated with a more rapid subsequent decline in iGFR in the HIV-positive group. Similarly, another study reported that viral suppression over time was associated with favorable changes in estimated GFR in patients with advanced HIV disease at baseline [11]. Additionally, a recent study from a North American consortium of HIV cohorts reported that the incidence of end-stage renal disease (ESRD) among HIV-positive patients that maintained durable viral suppression was similar to age-, sex-, and race-matched ESRD rates in the general population [12]. In contrast, we found no association between current CD4+ cell count and baseline iGFR or iGFR slope, consistent with a prior report [6]. Together, these findings suggest that uncontrolled HIV infection is associated with loss of kidney function and that durable viral suppression can normalize longitudinal GFR trajectory.

In the HIV-positive group, we found HCV coinfection to be associated with a significantly lower iGFR at baseline, but no significant difference in iGFR slope over time. HCV has been associated with CKD and ESRD in other studies [13]. However, it is difficult to disentangle HCV infection effects from associated socioeconomic and behavioral factors, including drug use [14–17]. In our study, we measured cocaine use, both by self-report and by urine drug screen. Despite a high prevalence of active cocaine use in the cohort, we found no association between cocaine use and baseline iGFR or iGFR slope.

We also found associations between carotid plaque and lower baseline iGFR and between higher pulse wave velocity and more rapid iGFR decline. These findings support the established link between cardiovascular and kidney disease in both the general [18] and HIV-positive populations [19]. In this nondiabetic sample, higher baseline glycosylated hemoglobin was associated with slower iGFR decline over time. The reason for this association is not clear, although diabetes has been associated with hyperfiltration [20,21] and our observed association may reflect increases in iGFR in patients with glucose intolerance at baseline.

This study is among the first to assess longitudinal kidney function changes in an HIV-positive sample using a gold-standard GFR measurement method. However, our study has limitations. First, the sample was predominantly African American, limiting the ability to extrapolate findings to other racial groups. Second, consistent with our research objectives, we excluded individuals with clinically decreased kidney function at baseline, preventing us from evaluating iGFR slopes in persons with overtly decreased kidney function. Third, a relatively small sample size and lack of longer-term follow-up may limit our ability to detect potentially clinically relevant associations, and multiple comparisons may increase the risk of identifying spurious associations.

In conclusion, compared with a demographically and behaviorally similar sample of HIV-negative participants, we found HIV-positive participants had significantly lower iGFR at baseline, despite similar estimated GFR values in the two groups. In contrast, there was no significant difference in iGFR decline over time by HIV status. In the HIV-positive group, HCV coinfection was associated with a lower baseline iGFR and nonsuppressed viral load at baseline was associated with a more rapid subsequent decline in iGFR. Other findings support albuminuria and cardiovascular disease as being strongly linked to kidney function loss over time in HIV-positive persons.

Acknowledgements

This project was funded by the National Institute on Drug Abuse (R01 DA026770, K24 DA035684). M.G.A. and D.M.F. were supported by NIH/NIDDK grant P01DK056492. Other support was provided by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by grant number UL1-TR000424 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH, and by the Johns Hopkins Center for AIDS Research (P30 AI094189). We want to thank Tracey Whoolery, April Stokes, and Paula Maier for their work on this study. We also want to acknowledge GE Healthcare for kindly providing the iohexol used for glomerular filtration rate measurements. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions: G.M.L. designed and obtained funding for the study and drafted the initial manuscript. M.G.A and D.M.F. provided nephrology expertise. J.H.S and G.J.S. provided expertise in cardiovascular assessment and iohexol-based glomerular filtration rate measurement, respectively. G.M.L., A.M.M., and S.H.M. analyzed data or contributed statistical expertise. All authors reviewed and approved the final manuscript.

Conflicts of interest

There are no conflicts of interest.

References

1. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e96–e138.
2. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367:20–29.
3. Bhasin B, Lau B, Atta MG, Fine DM, Estrella MM, Schwartz GJ, et al. HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C. PLoS One 2013; 8:e82028.
4. Gagneux-Brunon A, Delanaye P, Maillard N, Fresard A, Basset T, Alamartine E, et al. Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort. AIDS 2013; 27:1573–1581.
5. Inker LA, Wyatt C, Creamer R, Hellinger J, Hotta M, Leppo M, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr 2012; 61:302–309.
6. Margolick JB, Jacobson LP, Schwartz GJ, Abraham AG, Darilay AT, Kingsley LA, et al. Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection. PLoS One 2014; 9:e86311.
7. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612.
8. Schwartz GJ, Furth S, Cole SR, Warady B, Munoz A. Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int 2006; 69:2070–2077.
9. Stein JH, Korcarz CE, Mays ME, Douglas PS, Palta M, Zhang H, et al. A semiautomated ultrasound border detection program that facilitates clinical measurement of ultrasound carotid intima-media thickness. J Am Soc Echocardiogr 2005; 18:244–251.
10. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–381.
11. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22:481–487.
12. Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis 2015; 60:941–949.
13. Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008; 22:1799–1807.
14. Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013; 208:1240–1249.
15. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012; 26:1917–1926.
16. Fine DM, Garg N, Haas M, Rahman MH, Lucas GM, Scheel PJ, et al. Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol 2007; 2:1125–1130.
17. Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, et al. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012; 7:e40245.
18. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073–2081.
19. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24:387–394.
20. Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35:2061–2068.
21. Ng DK, Jacobson LP, Brown TT, Palella FJ Jr, Martinson JJ, Bolan R, et al. HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection. AIDS 2014; 28:377–386.
Keywords:

chronic kidney disease; glomerular filtration rate; HIV; HIV RNA; iohexol clearance; longitudinal

Supplemental Digital Content

Copyright © 2016 Wolters Kluwer Health, Inc.